PMCBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30

PharmaCyte Biotech, Inc.

Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 14, 2026

$0.34+0.00 (+0.53%)

Close on Oct 19, 2026

Market cap: $3.67M
P/E (TTM): –
Dividend yield: –

PharmaCyte Biotech, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-04-30	FY 2025 2025-04-30	FY 2024 2024-04-30	FY 2023 2023-04-30	FY 2022 2022-04-30	FY 2021 2021-04-30	FY 2020 2020-04-30	FY 2019 2019-04-30	FY 2018 2018-04-30	FY 2017 2017-04-30	FY 2016 2016-04-30	FY 2015 2015-04-30	FY 2014 2014-04-30	FY 2013 2013-04-30	FY 2012 2012-04-30	FY 2011 2011-04-30	FY 2010 2010-04-30
Cash & Equivalents	19	15	50	68	85	2.20	0.89	0.52	1.06	3.46	1.92	2.70	3.62	0.20	0.02	0.06	0.00
Short-Term Investments	0.25	0.37	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Cash & Short-Term Investments	19	16	50	68	85	2.20	0.89	0.52	1.06	3.46	1.92	2.70	3.62	0.20	0.02	0.06	0.00
Receivables	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.00	0.00	–
Inventory	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0.01	0.02	–
Prepaid Expenses & Other	0.10	0.22	0.26	0.11	0.09	0.07	0.14	0.14	0.22	0.07	0.11	1.47	0.57	0.13	0.16	0.03	–
Other Current Assets	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	–
Total Current Assets	37	22	50	68	85	2.28	1.04	0.65	1.28	3.54	2.03	4.17	4.19	1.85	1.06	0.10	–
Property, Plant & Equipment	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.05	–
Equity Method Investments	–	–	0	1.57	1.57	1.57	1.57	1.57	1.57	1.57	1.57	1.57	1.57	0	–	–	–
Intangible Assets	0	1.55	1.55	3.55	3.55	–	–	–	–	–	–	–	–	–	–	–	–
Other Long-Term Assets	0.01	0.01	–	–	–	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0	–	–	–
Total Assets	47	55	60	73	91	7.40	6.17	5.78	6.41	8.67	7.16	9.30	9.32	2.88	2.09	1.24	–
Accounts Payable	0.27	0.40	0.39	0.13	0.21	0.17	0.19	0.12	0.35	0.37	0.34	0.50	0.19	0.35	0.73	0.71	–
Accrued Expenses	0.52	2.52	0.74	0.46	0.50	0.55	0.82	0.62	0.29	0.21	0.15	0.02	0.04	0.01	0.41	0.27	–
Short-Term Debt	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2.37	–
Current Debt	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2.37	–
Other Current Liabilities	–	–	–	–	–	–	–	–	–	–	–	–	–	2.34	–	–	–
Total Current Liabilities	0.83	2.91	7.42	0.59	0.70	0.72	1.03	0.74	0.64	0.58	0.64	1.52	0.37	3.80	3.79	3.39	–
Long-Term Debt	–	–	–	–	–	–	–	–	–	–	–	–	–	0.02	–	–	–
Total Liabilities	12	3.28	20	0.59	0.70	0.72	1.08	0.74	0.64	0.58	0.64	1.52	0.37	3.80	3.79	3.39	–
Total Debt	–	–	–	–	–	–	–	–	–	–	–	–	–	0.02	–	2.37	–
Preferred Stock	0	0	0	0	–	–	–	0	–	–	–	0	0	0.58	0.58	–	–
Common Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.12	0.10	0.09	0.08	0.07	0.07	0.05	0.04	0.04	–
Additional Paid-In Capital	183	181	185	202	202	114	109	105	102	97	91	86	76	40	38	34	–
Retained Earnings	-104	-85	-116	-116	-112	-107	-104	-100	-96	-89	-85	-79	-69	-41	-40	-38	–
Treasury Stock	-45	-45	-42	-14	0	–	–	–	–	–	–	–	–	–	–	–	–
Comprehensive Income & Other	-0.02	-0.02	-0.02	-0.02	-0.02	-0.02	-0.02	-0.01	0.00	0.00	0.00	0.00	0	–	–	–	–
Shareholders' Equity	33	52	28	73	90	6.68	5.09	5.04	5.77	8.09	6.52	7.78	8.94	-1.50	-2.28	-2.73	-2.45
Total Equity	33	52	28	73	90	6.68	5.09	5.04	5.77	8.09	6.52	7.78	8.94	-1.50	-2.28	-2.73	-2.45
Total Liabilities & Equity	47	55	60	73	91	7.40	6.17	5.78	6.41	8.67	7.16	9.30	9.32	2.88	2.09	1.24	–
Shares Outstanding(shares)	11	6.80	8.04	17	21	1.59	1.09	0.79	0.68	0.60	0.52	0.49	0.46	0.32	0.28	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jul 31, 2026

Profitability, TTM

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2026: -45.6%

Financial strength

Current ratio: 40.30
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 2307.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.13
Dividend yield: –